Clinical Trial Update: Porphozym in the Treatment of Acute Attacks in AIP [Phase 2, Phase 3]

View source ↗

Summary

Porphozym is studied in a Phase 2/Phase 3 trial for acute attacks in Acute Intermittent Porphyria. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Porphyria

Drugs mentioned

• Porphozym

Snippet

Sponsor: Zymenex A/S | Conditions: Acute Intermittent Porphyria | Phase 2, Phase 3 | Status: COMPLETED